The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2023.
It is a great pleasure to have received the message from the EU Patent Office in Munich, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the EU Patent Office this March. The patent extents to the substance IML-106 for the treatment HIV infections and AIDS.
In the fight against coronaviruses the team of the ImmunoLogik identified a promising lead candidate for the treatment of people infected with SARS-CoV-2. The highly qualified ImmunoLogik Team around Dr. Christian Setz (Managing Director, formerly project leader at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) and the scientific advisor Prof. Dr. Ulrich Schubert (Professor for virology at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) present this funding project on aescuvest.de in summer 2020. Only here you have the chance to learn more about the concept, to use the information advantage and to become an investor.
It is a great pleasure to have received the message from the USA, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the US patent office this March. The patent extents to the substance IML-106 for the treatment HIV infections and AIDS.
The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2020.
The cooperation was and is still an important building block for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS.
The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2019.
The cooperation was and is still an important building block for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS.
On Sunday May 13th, the ImmunoLogik team around the CEO Dr. Christian Setz and the scientific advisor Prof. Dr. Ulrich Schubert successfully finsihed their crowdinvesting campaign on aescuvest.
More than 200 investors decided to invest together over 300.000 € in the innovative development of the lead candidate IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS.
On Sunday November 26th, the ImmunoLogik team around the CEO Dr. Christian Setz and the scientific advisor Prof. Dr. Ulrich Schubert started their crowdinvesting campaign on aescuvest. Only there you have the chance to invest and participate in the innovative development of the lead candidate IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS.
The highly qualified ImmunoLogik Team around Dr. Christian Setz (CEO, formerly project leader for HIV-1 at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) and the scientific advisor Prof. Dr. Ulrich Schubert (Professor for virology at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) will present this funding project on aescuvest in fall 2017. Only here you have the chance to learn more about the concept, to use the information advantage and to become an investor.
